This is slowly turning into a long-term story. We have reported on Vidac Pharma plc several times in recent weeks. There has been tremendous interest in the stock recently, and even with a premium of 300% at the peak, there are now further potential buyers. Last week, the price briefly reached EUR 1.30, which seems a bit excessive in such a short time. At the peak, around 4 million shares changed hands. Since the last report on the granting of a patent for extensive protection of the mode of action of its cancer drug candidates, there have been no new insights. Presumably, expectations are high for further progress in the Israeli research program at the upcoming medical conferences in Q4, particularly regarding the drug candidates VDA-1102 and VDA-1275.